S. Sugarman
Impact in
- Oncology top 10%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
-
- Breast Cancer Treatment Studies
Papers in
- Oncology 14
- Cancer Treatment and Pharmacology 11
- Neutropenia and Cancer Infections 3
- Colorectal Cancer Treatments and Studies 2
- HER2/EGFR in Cancer Research 2
- Lung Cancer Research Studies 2
-
- Breast Cancer Treatment Studies 5
- Co-authors
- Richard Pazdur (3 shared papers)Jaffer A. Ajani (2 shared papers)Yvonne Lassere (2 shared papers)Yehuda Z. Patt (2 shared papers)James L. Abbruzzese (2 shared papers)Verna A. Rhodes (1 shared paper)Avi B. Markowitz (2 shared papers)C. Hudis (3 shared papers)
- Journals
- Journal of Clinical Oncology (6 papers)Cancer Research (3 papers)Breast Cancer Research and Treatment (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)Experimental Biology and Medicine (1 paper)
- Partner nations
- United StatesSingapore
In The Last Decade
S. Sugarman
16 papers receiving 395 citations
Peers
Comparison fields: 5 of 52
- Oncology 332
- Cancer Research 50
- Hepatology 25
- Pulmonary and Respiratory Medicine 100
- Pathology and Forensic Medicine 47
Countries citing papers authored by S. Sugarman
This map shows the geographic impact of S. Sugarman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Sugarman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Sugarman more than expected).
Fields of papers citing papers by S. Sugarman
This network shows the impact of papers produced by S. Sugarman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Sugarman. The network helps show where S. Sugarman may publish in the future.
Co-authors
The 25 scholars most cited alongside S. Sugarman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1994 | 170 | |
| 2 | 2008 | 50 | |
| 3 | 1994 | 44 | |
| 4 | 1996 | 33 | |
| 5 | 2000 | 32 | |
| 6 | 2016 | 20 | |
| 7 | Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. | 1996 | 16 |
| 8 | 2006 | 13 | |
| 9 | 2009 | 11 | |
| 10 | 2011 | 7 | |
| 11 | 2007 | 5 | |
| 12 | 1995 | 2 | |
| 13 | 1968 | 2 | |
| 14 | 2009 | 2 | |
| 15 | 2009 | 2 | |
| 16 | 2008 | 1 |
About S. Sugarman
S. Sugarman is a scholar working on Oncology, Cancer Research, Molecular Biology, Cardiology and Cardiovascular Medicine and Dermatology, having authored 16 papers that have together received 410 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (5 papers), Neutropenia and Cancer Infections (3 papers), Chemotherapy-induced cardiotoxicity and mitigation (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Cancer therapeutics and mechanisms (2 papers), HER2/EGFR in Cancer Research (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Oncology (332 citations), Cancer Research (50 citations), Hepatology (25 citations), Pulmonary and Respiratory Medicine (100 citations) and Pathology and Forensic Medicine (47 citations). S. Sugarman has collaborated with scholars based in United States and Singapore. Frequent co-authors include Richard Pazdur, Jaffer A. Ajani, Yvonne Lassere, Yehuda Z. Patt, James L. Abbruzzese, Verna A. Rhodes, Avi B. Markowitz, C. Hudis, Wen Ma and Alison L. Hannah. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Cancer Chemotherapy and Pharmacology and Experimental Biology and Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.